<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="771">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04467008</url>
  </required_header>
  <id_info>
    <org_study_id>2020/05</org_study_id>
    <nct_id>NCT04467008</nct_id>
  </id_info>
  <brief_title>Covid-19 Rapid Diagnostic Tests on Blood Drop</brief_title>
  <acronym>COVID-TEST</acronym>
  <official_title>Evaluation of Covid-19 Rapid Diagnostic Tests on Blood Drop</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CMC Ambroise Paré</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CMC Ambroise Paré</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the diagnostic reliability of the Biosynex rapid blood test for&#xD;
      Covid-19 infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Covid-19 pandemic requires a reliable diagnosis of affected patients in order to manage&#xD;
      them in an appropriate manner, in the appropriate departments. Furthermore, the diagnostic&#xD;
      reference at the time of this study is based on reverse transcription by reaction in&#xD;
      polymerase chain reaction (RT-PCR) on a nasopharyngeal swab taken. This method has may yield&#xD;
      false negatives (up to 30% depending on the series) and its lead time is several hours.&#xD;
&#xD;
      Alternatives are therefore being developed, in particular rapid blood tests. The rapid&#xD;
      diagnostic test distributed by Biosynex has been evaluated by the National Reference Center&#xD;
      for Respiratory Infections Viruses as very specific for the detection of IgG + IgM (93%).&#xD;
&#xD;
      As part of the evaluation of this test, it was used in patients with severe Covid-19 disease,&#xD;
      requiring hospitalization in critical care in order to be able to establish their reliability&#xD;
      in a clinical context where many confounding factors may occur, such as lymphopenia or&#xD;
      systemic inflammation. However, the early diagnosis of this patient population remains&#xD;
      critical in order to be able to refer them to the appropriate services.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Actual">August 15, 2020</completion_date>
  <primary_completion_date type="Actual">August 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positivity of the rapid diagnostic test</measure>
    <time_frame>Immediate, up to 1 day.</time_frame>
    <description>Positivity of the rapid diagnostic test, assessed by the presence of either IgM or IgG</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">113</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>One group of patients</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed COVID-19 pneumonia (using RT-PCR) who required hospitalization in&#xD;
        intensive care unit.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed COVID-19 diagnosis with at least one positive RT-PCR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee Nguyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CMC Ambroise Paré</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMC Ambroise Paré</name>
      <address>
        <city>Neuilly-sur-Seine</city>
        <zip>92200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 9, 2020</study_first_submitted>
  <study_first_submitted_qc>July 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid 19</keyword>
  <keyword>Diagnostic</keyword>
  <keyword>Biosynex</keyword>
  <keyword>Blood drop</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

